Status:
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Lead Sponsor:
Amgen
Conditions:
Non-Small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
November 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2031
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT05920356
Start Date
November 16 2023
End Date
June 30 2031
Last Update
February 27 2026
Active Locations (379)
Enter a location and click search to find clinical trials sorted by distance.
1
Sansum Clinic
Santa Barbara, California, United States, 93105
2
Medical Oncology Hematology Consultants Helen F Graham Cancer Center
Newark, Delaware, United States, 19713
3
University of Illinois Chicago
Chicago, Illinois, United States, 60612
4
Illinois Cancer Specialists
Niles, Illinois, United States, 60714